Fröss-Baron K - Search Results

1

In Vivo Instability of ¹⁷⁷Lu-DOTATATE During Peptide Receptor Radionuclide Therapy.

Lubberink M, Wilking H, Öst A, Ilan E, Sandström M, Andersson C, Fröss-Baron K, Velikyan I, Sundin A. Lubberink M, et al. Among authors: fross baron k. J Nucl Med. 2020 Sep;61(9):1337-1340. doi: 10.2967/jnumed.119.237818. Epub 2020 Jan 31. J Nucl Med. 2020. PMID: 32005767 Free PMC article.

2

Prospective observational study of ¹⁷⁷Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity.

Garske-Román U, Sandström M, Fröss Baron K, Lundin L, Hellman P, Welin S, Johansson S, Khan T, Lundqvist H, Eriksson B, Sundin A, Granberg D. Garske-Román U, et al. Among authors: fross baron k. Eur J Nucl Med Mol Imaging. 2018 Jun;45(6):970-988. doi: 10.1007/s00259-018-3945-z. Epub 2018 Mar 1. Eur J Nucl Med Mol Imaging. 2018. PMID: 29497803 Free PMC article.

3

Favorable Outcome in Patients with Pheochromocytoma and Paraganglioma Treated with ¹⁷⁷Lu-DOTATATE.

Vyakaranam AR, Crona J, Norlén O, Granberg D, Garske-Román U, Sandström M, Fröss-Baron K, Thiis-Evensen E, Hellman P, Sundin A. Vyakaranam AR, et al. Among authors: fross baron k. Cancers (Basel). 2019 Jun 28;11(7):909. doi: 10.3390/cancers11070909. Cancers (Basel). 2019. PMID: 31261748 Free PMC article.

4

177Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated with Chemotherapy: Analysis of Outcome, Safety, and Their Determinants.

Fröss-Baron K, Garske-Roman U, Welin S, Granberg D, Eriksson B, Khan T, Sandström M, Sundin A. Fröss-Baron K, et al. Neuroendocrinology. 2021;111(4):330-343. doi: 10.1159/000506746. Epub 2020 Feb 25. Neuroendocrinology. 2021. PMID: 32097917 Free article.

5

Tumor Contrast-Enhancement for Monitoring of PRRT ¹⁷⁷Lu-DOTATATE in Pancreatic Neuroendocrine Tumor Patients.

Pettersson O, Fröss-Baron K, Crona J, Sundin A. Pettersson O, et al. Among authors: fross baron k. Front Oncol. 2020 Feb 21;10:193. doi: 10.3389/fonc.2020.00193. eCollection 2020. Front Oncol. 2020. PMID: 32154181 Free PMC article.

6

Kidney dosimetry in 777 patients during ¹⁷⁷Lu-DOTATATE therapy: aspects on extrapolations and measurement time points.

Sandström M, Freedman N, Fröss-Baron K, Kahn T, Sundin A. Sandström M, et al. Among authors: fross baron k. EJNMMI Phys. 2020 Dec 9;7(1):73. doi: 10.1186/s40658-020-00339-2. EJNMMI Phys. 2020. PMID: 33296054 Free PMC article.

7

Tumor growth rate in pancreatic neuroendocrine tumor patients undergoing PRRT with 177Lu-DOTATATE.

Pettersson OJ, Fröss-Baron K, Crona J, Sundin A. Pettersson OJ, et al. Among authors: fross baron k. Endocr Connect. 2021 Apr 22;10(4):422-431. doi: 10.1530/EC-21-0027. Endocr Connect. 2021. PMID: 33875614 Free PMC article.

8

Receptor depletion and recovery in small-intestinal neuroendocrine tumors and normal tissues after administration of a single intravenous dose of octreotide measured by ⁶⁸Ga-DOTATOC PET/CT.

Jahn U, Ilan E, Velikyan I, Fröss-Baron K, Lubberink M, Sundin A. Jahn U, et al. Among authors: fross baron k. EJNMMI Res. 2021 Nov 25;11(1):118. doi: 10.1186/s13550-021-00860-0. EJNMMI Res. 2021. PMID: 34822040 Free PMC article.

9

Hypoalbuminemia, but not derived neutrophil to lymphocyte ratio (dNLR), predicts overall survival in neuroendocrine tumours undergoing peptide receptor radionuclide therapy: A retrospective, cohort study of 557 patients.

Papantoniou D, Fröss-Baron K, Garske-Román U, Sundin A, Thiis-Evensen E, Grönberg M, Welin S, Tiensuu Janson E. Papantoniou D, et al. Among authors: fross baron k. J Neuroendocrinol. 2024 Mar 13:e13379. doi: 10.1111/jne.13379. Online ahead of print. J Neuroendocrinol. 2024. PMID: 38477040

10

Radio-guided surgery with the use of [99mTc-EDDA/HYNIC]octreotate in intra-operative detection of neuroendocrine tumours of the gastrointestinal tract.

Hubalewska-Dydejczyk A, Kulig J, Szybinski P, Mikolajczak R, Pach D, Sowa-Staszczak A, Fröss-Baron K, Huszno B. Hubalewska-Dydejczyk A, et al. Among authors: fross baron k. Eur J Nucl Med Mol Imaging. 2007 Oct;34(10):1545-55. doi: 10.1007/s00259-007-0476-4. Epub 2007 Jul 25. Eur J Nucl Med Mol Imaging. 2007. PMID: 17653543 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

13 results

Search Page